Lineage Cell Therapeutics, Inc. (LCTX) Stock Score, Valuation & Financial Research
Lineage Cell Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 29/100.
Quick answer for LCTX
Lineage Cell Therapeutics, Inc. currently has a Wall Street Score of 29/100. The stored market price is $1.07. Its financial score is 37/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Lineage Cell Therapeutics, Inc. does
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In additio
LCTX financial snapshot
- Wall Street Score:
- 29/100
- Current price:
- $1.07
- Market capitalization:
- $265.5M
- Revenue:
- $13.1M
- Net income:
- $-32.3M
- Free cash flow:
- $-19.4M
- Cash:
- $37.4M
- Total debt:
- $2.3M
- EPS:
- -0.14
- Financial score:
- 37/100
- Valuation score:
- 0/100
- Revenue score:
- 21/100
What stands out
- Reported year-over-year revenue growth is -0.1%.
- Free cash flow is $-19.4M, showing cash burn in the current stored period.
- The balance sheet shows $37.4M of cash versus $2.3M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 37/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-07.
How to research LCTX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.